Abstract
Disruption of a proper regulation of cell proliferation can ultimately cause cancer. Most human B cell malignancies are driven by chromosomal translocations or other genetic alterations which directly affect the function of critical cell cycle proteins, such as cyclins and cyclin-dependent kinases. In addition, the transformation of indolent lymphomas into aggressive malignancies is often accompanied by a loss of tumor suppressors controlling important cell cycle checkpoints. A better understanding of cell cycle deregulations in human tumors has promoted the introduction of a new class of antiproliferative drugs into cancer therapies. These drugs exert their function by specifically blocking important cell cycle proteins. In the present review we discuss how alterations in the cell cycle control contribute to the malignant transformation of B cells. Furthermore, we provide an overview of novel direct and indirect cell cycle inhibitors and their impact on the treatment of patients with B cell lymphomas.
Keywords: Cell cycle regulation, lymphoma, target therapy
Current Drug Targets
Title: Cell Cycle Inhibition in Malignant Lymphoma: Disease Control by Attacking the Cellular Proliferation Machinery
Volume: 7 Issue: 10
Author(s): Ingo Ringshausen, Christian Peschel and Thomas Decker
Affiliation:
Keywords: Cell cycle regulation, lymphoma, target therapy
Abstract: Disruption of a proper regulation of cell proliferation can ultimately cause cancer. Most human B cell malignancies are driven by chromosomal translocations or other genetic alterations which directly affect the function of critical cell cycle proteins, such as cyclins and cyclin-dependent kinases. In addition, the transformation of indolent lymphomas into aggressive malignancies is often accompanied by a loss of tumor suppressors controlling important cell cycle checkpoints. A better understanding of cell cycle deregulations in human tumors has promoted the introduction of a new class of antiproliferative drugs into cancer therapies. These drugs exert their function by specifically blocking important cell cycle proteins. In the present review we discuss how alterations in the cell cycle control contribute to the malignant transformation of B cells. Furthermore, we provide an overview of novel direct and indirect cell cycle inhibitors and their impact on the treatment of patients with B cell lymphomas.
Export Options
About this article
Cite this article as:
Ringshausen Ingo, Peschel Christian and Decker Thomas, Cell Cycle Inhibition in Malignant Lymphoma: Disease Control by Attacking the Cellular Proliferation Machinery, Current Drug Targets 2006; 7 (10) . https://dx.doi.org/10.2174/138945006778559210
DOI https://dx.doi.org/10.2174/138945006778559210 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Characterization of the Lymphotropic Amplicons-6 and Tamplicon-7 Vectors Derived from HHV-6 and HHV-7
Current Gene Therapy Meeting Report: The Fourth Annual PepTalk Meeting: The Human Proteome
Current Proteomics NF-κB Signaling Pathway Inhibitors as Anticancer Drug Candidates
Anti-Cancer Agents in Medicinal Chemistry Anti-breast Cancer Potential of Natural and Synthetic Coumarin Derivatives
Current Topics in Medicinal Chemistry Feasibility of FDG PET in Inflammatory Bowel Disease
Current Molecular Imaging (Discontinued) Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Novel Insights in Molecular Mechanisms of CLL
Current Pharmaceutical Design Novel Beta-Lactam Antibiotics Derivatives: Their New Applications as Gene Reporters, Antitumor Prodrugs and Enzyme Inhibitors
Mini-Reviews in Medicinal Chemistry Oxaliplatin Based Chemotherapy and Concomitant Highly Active Antiretroviral Therapy in the Treatment of 24 Patients with Colorectal Cancer and HIV Infection
Current HIV Research The Blood-Brain Barrier in Multiple Sclerosis: microRNAs as Key Regulators
CNS & Neurological Disorders - Drug Targets The Aging of the Adaptive Immune System
Current Immunology Reviews (Discontinued) C-KIT Signaling in Cancer Treatment
Current Pharmaceutical Design Recent Advances in the Development of Dual Topoisomerase I and II Inhibitors as Anticancer Drugs
Current Medicinal Chemistry New and Under Explored Epigenetic Modulators in Search of New Paradigms
Medicinal Chemistry Modulation of Angiogenesis for Cancer Prevention: Strategies Based On Antioxidants and Copper Deficiency
Current Pharmaceutical Design Lactoferricin Derived From Milk Protein Lactoferrin
Current Pharmaceutical Design Expansion or Depletion of T Follicular Helper Cells During HIV Infection: Consequences for B cell Responses
Current HIV Research Removal of the Tag from His-tagged ILYd4, a Human CD59 Inhibitor, Significantly Improves its Physical Properties and its Activity
Current Pharmaceutical Design Lichen Depsidones as Potential Novel Pharmacologically Active Compounds
Mini-Reviews in Organic Chemistry Treatment for Cancer Patients with Oral Mucositis: Assessment Based on the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer in International Society of Oral Oncology (MASCC/ISOO) in 2013 and Proposal of Possible Novel Treatment with a Japanese Herbal Medicine
Current Pharmaceutical Design